Precision Neuroscience Corp Overview
Pro stress-test →Precision Neuroscience offers a platform for next generation brain-computer interface technology, targeting treatment of neurological conditions including spinal cord injuries, stroke, paralysis, and epilepsy. The company is building a minimally invasive brain–computer interface with a thin-film microelectrode array that conforms to the brain surface without penetrating the brain tissue.
Strategic Profile
Pro stress-test →Founded in 2021 by Michael Mager, Benjamin Rapoport and Mark Hettick, the company is well-positioned in the growing neurotech market. In December 2024, Precision Neuroscience raised $102M in Series C funding, bringing total capitalization to $183M across six rounds, with ~117 employees as of January 2026.
Competitive Landscape
Pro stress-test →Precision Neuroscience competes in the emerging BCI market against companies like Synchron (endovascular BCI), Neuralink (invasive electrode approach), and academic/clinical research programs at institutions such as Stanford and MIT. Its minimally-invasive, surface-conforming electrode design differentiates from both invasive and non-invasive competing approaches, targeting faster clinical adoption pathways.
Industry Context
Precision Neuroscience Corp operates in Brain-Computer Interface (BCI) Devices.
Key facts
Founded: 2021 · Headquarters: New York, US · Employees: 117